Michael A Freitas, PhD
College of Medicine
Cancer Biology and Genetics
Molecular Biology and Cancer Genetics
Leukemia, Lymphocytic, Chronic, B-Cell ● Precursor Cell Lymphoblastic Leukemia-Lymphoma
Michael Freitas, PhD, is a member of the Molecular Biology and Cancer Genetics Program at the OSUCCC – James, where he focuses his research on proteomics.He also is involved in biomarker discovery and validation, as well as bioinformatics for mass spectrometry-based proteomics. In particular, he works to determine the side-chain modifications of proteins in chromatin remodeling and relate them to aberrant cellular function in cancer. Among his recent research projects is a study that indicates the potential of the CD44 molecule as a prognostic biomarker in patients with multiple myeloma. An associate professor in the Department of Cancer Biology and Genetics at Ohio State, where he also directs the Proteomics Shared Resource for the OSUCCC – James, Dr. Freitas has authored or co-authored dozens of articles in well-respected publications, such as Journal of Proteomics, Molecular & Cellular Proteomics, Journal of Proteome Research and Nucleic Acids Research.